Low relapse rate leads to high concordance of sustained virologic response (SVR) at 12 weeks with SVR at 24 weeks after treatment with ABT-450/ritonavir, ombitasvir, and dasabuvir plus ribavirin in subjects with chronic hepatitis c virus genotype 1 infection in the AVIATOR study

Fred Poordad, Kosh Agarwal, Ziad Younes, Daniel Cohen, Wangang Xie, Thomas Podsadecki

Producción científica: Articlerevisión exhaustiva

21 Citas (Scopus)

Resumen

In 247 subjects with hepatitis C virus genotype 1 infection treated with the interferon-free regimen of ABT-450/ritonavir, ombitasvir, and dasabuvir plus ribavirin, concordance of a sustained virologic response at 12 and 24 weeks supports the use of the earlier time point as a primary efficacy endpoint for trials of this interferon-free regimen.

Idioma originalEnglish (US)
Páginas (desde-hasta)608-610
Número de páginas3
PublicaciónClinical Infectious Diseases
Volumen60
N.º4
DOI
EstadoPublished - feb 15 2015

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases

Huella

Profundice en los temas de investigación de 'Low relapse rate leads to high concordance of sustained virologic response (SVR) at 12 weeks with SVR at 24 weeks after treatment with ABT-450/ritonavir, ombitasvir, and dasabuvir plus ribavirin in subjects with chronic hepatitis c virus genotype 1 infection in the AVIATOR study'. En conjunto forman una huella única.

Citar esto